To hear about similar clinical trials, please enter your email below
Trial Title:
Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma
NCT ID:
NCT05577884
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
noncontrast-enhanced whole-body CT
Description:
noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube
(75% radiation) and B-tube (25% radiation).
- conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with
iterative reconstruction
- ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning
commercially available software.
Arm group label:
Multiple myeloma
Summary:
This prospective study aims to perform intra-individual comparison of the image quality
between ultra-low-dose whole-body CT with deep learning reconstruction and conventional
low-dose whole-body CT with iterative reconstruction in patients with suspected multiple
myeloma.
Criteria for eligibility:
Study pop:
Patients who are referred to Hemoatooncology department with suspicion of multiple
myeloma
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- signed informed consent
- patients with suspected multiple myeloma and scheduled for noncontrast-enhanced
low-dose whole-body CT
- patients who have no previous history of chemotherapy for multiple myeloma
Exclusion Criteria:
- patients who do not agree to the protocol
- non-Korean patients
- pregnancy
Gender:
All
Minimum age:
19 Years
Maximum age:
85 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Seoul National University Hospital
Address:
City:
Seoul
Zip:
03080
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Hee-Dong Chae, MD
Phone:
+82-2-2072-4209
Email:
hdchae02@gmail.com
Investigator:
Last name:
Hee-Dong Chae, MD
Email:
Principal Investigator
Start date:
October 6, 2022
Completion date:
February 28, 2023
Lead sponsor:
Agency:
Seoul National University Hospital
Agency class:
Other
Source:
Seoul National University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05577884
